Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

18 nov. 2024 04h00 HE | Source: Quell TX

Quell Therapeutics Achieves Milestone for Type 1 Diabetes CAR-Treg Cell Therapy Program

Achievement of first significant research milestone triggers an option exercise payment of $10 million from AstraZenecaAstraZeneca will progress preclinical and clinical development of the selected...
10 juil. 2024 07h00 HE | Source: Quell TX

Quell Therapeutics Appoints Experienced Biopharma Leader Luke Beshar as Independent Chair of its Board of Directors

Quell Therapeutics Appoints Experienced Biopharma Leader Luke Beshar as Independent Chair of its Board of Directors London, UK – July 10, 2024 – Quell Therapeutics Ltd (“Quell”), a world leader in...
11 mars 2021 07h00 HE | Source: AIM ImmunoTech Inc.

AIM ImmunoTech to Present at the Q1 Virtual Investor Summit on March 24th

OCALA, Fla., March 11, 2021 (GLOBE NEWSWIRE) -- via InvestorWire – AIM ImmunoTech Inc. (NYSE American: AIM) today announced that Thomas K. Equels, Chief Executive Officer of AIM ImmunoTech, will be...